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A B S T R A C T
Purpose
Information about symptomatic toxicities of anticancer treatments is not based on direct report by
patients, but rather on reports by clinicians in trials. Given the potential for under-reporting, our aim
was to compare reporting by patients and physicians of six toxicities (anorexia, nausea, vomiting,
constipation, diarrhea, and hair loss) within three randomized trials.
Patients and Methods
In one trial, elderly patients with breast cancer received adjuvant chemotherapy; in two trials,
patients with advanced non–small-cell lung cancer received first-line treatment. Toxicity was
prospectively collected by investigators (graded by National Cancer Institute Common Toxicity
Criteria [version 2.0] or Common Terminology Criteria for Adverse Events [version 3]). At the end
of each cycle, patients completed the European Organisation for Research and Treatment of
Cancer quality-of-life questionnaires, including toxicity-related symptom items. Possible answers
were “not at all,” “a little,” “quite a bit,” and “very much.” Analysis was limited to the first three
cycles. For each toxicity, agreement between patients and physicians and under-reporting by
physicians (ie, toxicity reported by patients but not reported by physicians) were calculated.
Results
Overall, 1,090 patients (2,482 cycles) were included. Agreement between patients and physicians
was low for all toxicities. Toxicity rates reported by physicians were always lower than those
reported by patients. For patients who reported toxicity (any severity), under-reporting by
physicians ranged from 40.7% to 74.4%. Examining only patients who reported “very much”
toxicity, under-reporting by physicians ranged from 13.0% to 50.0%.
Conclusion
Subjective toxicities are at high risk of under-reporting by physicians, even when prospectively
collected within randomized trials. This strongly supports the incorporation of patient-reported
outcomes into toxicity reporting in clinical trials.
J Clin Oncol 33:910-915. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Information available to oncologists and their pa-
tients about symptomatic toxicities of anticancer
treatments is not based on direct report by prior
patients, but instead on reports made by clinician
assessment in clinical trials.1 The potential for
under-reporting of toxicity may be significant.2,3
The accurate description of occurrence and se-
verity of toxicity of anticancer agents is crucial for an
informed evaluation of their risk-benefit ratio. In a
randomized trial, under-reporting of toxicity does
not necessarily bias the direct comparison between
the treatments, if the under-reporting rate is similar
between treatment arms. However, it could substan-
tially affect absolute estimates of toxicity, which is
highly relevant for the applicability of trial results in
clinical practice, particularly for new drugs.
Approximately 20 years ago, the Outcomes
Working Group of the American Society of Clinical
Oncology Health Research Committee defined the
outcomes to be used for technology assessment and
development of cancer treatment guidelines. Toxic-
ity was considered a vitally important outcome.4 In
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that article, the authors underlined that the evaluation of a subjec-
tive toxicity starts by explicitly asking the patient whether that
toxicity occurred, highlighting that even if the patient does not
report toxic symptoms voluntarily, this does not imply that the
toxicity did not occur.4
In a modern view of evidence-based practice, satisfying com-
munication between patients with cancer and their physicians
about benefits and risks associated with treatments is a critical
component of care, ensuring that patients’ preferences are taken
into account in decision making.5 In recent years, reflecting an
increasing focus on a patient-centered approach, scientific interest
in the integration of patient-reported outcomes into drug safety
evaluation and comparative-effectiveness research is growing.6
The aim of this study was to describe patients’ and physicians’
reporting of six symptomatic toxicities occurring during anticancer
treatment, based on data prospectively collected in randomized trials,
to describe the agreement between patients’ and physicians’ reports
and the rate of possible under-reporting by physicians.
PATIENTS AND METHODS
Patients enrolled onto three randomized controlled trials, all coordinated by
the Clinical Trials Unit of the National Cancer Institute (Napoli, Italy) were
included in this analysis. In the ELDA (Elderly Breast Cancer—Docetaxel
Adjuvant) study (ClinicalTrials.gov identifier NCT00331097),7 patients age 65
to 79 years with early-stage breast cancer and Eastern Cooperative Oncology
Group (ECOG) performance status of 0 to 1 were randomly assigned to receive
adjuvant cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluo-
rouracil 600 mg/m2 intravenously (IV) on days 1 and 8 every 4 weeks or
docetaxel 35 mg/m2 on days 1, 8, and 15 every 4 weeks. Between July 2003 and
April 2011, 299 patients were randomly assigned in Italian institutions.
In the GECO (Gemcitabine–Coxib) trial of non–small-cell lung cancer
(NSCLC; ClinicalTrials.gov identifier NCT00385606),8 patients age  70
years with advanced NSCLC and ECOG performance status of 0 to 1 were
randomly assigned to one of four treatment groups: arm A, gemcitabine 1,200
mg/m2 in a 30-minute IV infusion on days 1 and 8 plus cisplatin 80 mg/m2 IV
on day 1, every 21 days; arm B, same as arm A plus oral rofecoxib 50 mg daily;
arm C, prolonged constant IV gemcitabine 1,200 mg/m2 over 120-minute
infusion on days 1 and 8 plus cisplatin 80 mg/m2 IV on day 1, every 21 days;
and arm D, same as arm C plus oral rofecoxib 50 mg daily. Between January
2003 and May 2005, 400 patients were enrolled in Italian institutions.
In the TORCH (Tarceva or Chemotherapy) trial (ClinicalTrials.gov
identifier NCT00349219),9 patients with advanced NSCLC and ECOG perfor-
mance status of 0 to 1 were randomly assigned to first-line cisplatin 80 mg/m2
IV on day 1 plus gemcitabine 1,200 mg/m2 IV on days 1 and 8 every 3 weeks or
erlotinib 150 mg per day orally; erlotinib administration was conventionally
divided into 3-week cycles. Between December 2006 and November 2009, 760
patients were randomly assigned, 612 in Italy (age  70 years) and 148 in
Canada (without age limit).
All three trials were approved by the ethical committee of each par-
ticipating institution. All patients signed written informed consent before
enrollment in each trial. Treatment cycles were evaluable for our analysis if
both toxicity evaluation and health-related quality-of-life (QoL) informa-
tion were available in the study database. Analysis was limited to the first
three treatment cycles.
Toxicity was prospectively collected by investigators. A paper case report
form (CRF; sent by fax to coordinating center) was used for two trials (ELDA
and GECO), and a Web-based CRF was available for the TORCH trial through
the Web site of the coordinating center. The CRF (either paper or Web based)
was prepopulated with a specific list of adverse events (including those de-
scribed in our analysis), and the worst grade (from 0 to highest one) for each
adverse event was collected at the end of each cycle. Toxicity was coded
according to the National Cancer Institute (NCI) Common Toxicity Criteria
(version 2.0) in GECO and ELDA and the NCI Common Terminology Crite-
ria for Adverse Events (CTCAE; version 3) in TORCH. Coding of the six
toxicities considered in our analysis was the same in the two different versions
of the NCI CTCAE used. For our analysis, any grade coded by the physician as
 0 was deemed “toxicity reported by the physician,” whatever the grade. For
all six toxicities, according to the scales adopted, even the mildest toxicities
should have been reported as grade 1.
At the end of each treatment cycle, patients completed the European
Organisation for Research and Treatment of Cancer (EORTC) QoL question-
naires. The core questionnaire (QLQ-C30)10 was used in all the three trials,
along with the lung cancer–specific module (QLQ-LC13)11 in the GECO and
TORCH trials and the breast cancer–specific module (QLQ-BR23)12 in the
ELDA trial. These instruments are designed to be completed by the patient.
Anorexia, nausea, vomiting, constipation, and diarrhea are assessed by one
item each in the QLQ-C30 questionnaire: items 13 (have you lacked appetite?),
14 (have you felt nauseated?), 15 (have you vomited?), 16 (have you been
constipated?), and 17 (have you had diarrhea?). Hair loss is assessed by one
item in QLQ-LC13 (item 39 [have you had hair loss?]) and one in QLQ-BR23
(item 34 [have you lost any hair?]). These questions specifically refer to the
previous week. The items are scored in four categories (not at all, a little, quite
a bit, or very much). All responses different from “not at all” (ie, a little, quite a
bit, and very much) were pooled together as “any severity” or simply “any,”
followed by the name of the adverse effect.
All results are reported per patient (ie, patient was unit of analysis),
overall and separately by trial. A complementary per-cycle analysis, with cycle
as unit of analysis, is reported in the Data Supplement. In the per-patient
analysis, agreement between patient and physician evaluations was assessed by
Cohen’s .13 Although there is no universal definition of the interpretation of
 values, according to Fleiss,14  values  0.40 can be interpreted as poor
agreement, values between 0.40 and 0.75 as moderate to good agreement, and
values 0.75 as excellent agreement. Under-reporting was calculated as the
rate of cases where physicians reported grade 0 toxicity in all the cycles, of cases
where patients reported toxicity in  one cycle. In the per-cycle analysis,
under-reporting was calculated as the rate of cycles where physicians reported
grade 0, of cycles where patients reported toxicity. In the per-patient approach,
two different analyses were performed, the first in all patients reporting any
toxicity and the second limited to those patients reporting “very much” toxic-
ity. A similar approach was used also in the per-cycle analysis.
RESULTS
Overall, of 1,459 patients enrolled onto the three randomized trials,
1,090 patients (enrolled by 78 institutions in two countries) were
eligible for this analysis (because of availability of toxicity information
and QoL questionnaire for one of first three cycles), for a total of
2,482 evaluable cycles. Compared with noneligible patients, those
eligible more frequently had performance status of 0 and were of
Canadian origin; also, eligible patients received a slightly higher mean
number of cycles and, according to physician assessment, experienced
more toxicity for all the analyzed items (Data Supplement). As out-
lined in Figure 1, 986 patients were assessed for cycle one, 840 for cycle
two, and 656 for cycle three. The main characteristics of patients
included are summarized in Table 1.
Patient reports of anorexia (of any severity) were documented in
679 (62.3%) of 1,090 patients, nausea in 654 (60.0%) of 1,089, vomit-
ing in 283 (26.0%) of 1,090, constipation in 554 (51.0%) of 1,087,
diarrhea in 388 (35.7%) of 1,088, and hair loss in 552 (50.8%) of 1,086.
Physician reports of anorexia (of any grade) were documented in 202
(18.5%) of 1,090 patients, nausea in 488 (44.8%) of 1,089, vomiting in
256 (23.5%) of 1,090, constipation in 202 (18.6%) of 1,087, diarrhea in
248 (22.8%) of 1,088, and hair loss in 207 (19.1%) of 1,086.
Agreement Between Patient and Physician Reporting of Toxicities
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Table 2 describes the agreement between patient reporting (any
severity) and physician reporting (any grade) of toxicity in all patients.
For the six toxicities, Cohen’s  ranged between 0.15 and 0.45, which
can be interpreted as poor to moderate agreement. In all cases, per-
centages of toxicities reported by patients were higher than those
reported by physicians. As shown in Figure 2, considering only pa-
tients who reported any toxicity, the proportion of under-reporting by
physicians (ie, patients for whom physicians reported grade 0) was
74.4% for anorexia, 40.7% for nausea, 47.3% for vomiting, 69.3% for
constipation, 50.8% for diarrhea, and 65.2% for hair loss. Some het-
erogeneity among trials was evident only for diarrhea, which was more
frequently under-reported in GECO, and hair loss, which was less
frequently under-reported in ELDA. Detailed numbers of the under-
reporting, in the pooled data set and by trial and according to different
treatment arms of each trial, are reported in the Data Supplement.
When examining only patients who reported “very much” tox-
icity in any cycle, the proportion of under-reporting by physicians was
50.0% for anorexia, 25.8% for nausea, 13.0% for vomiting, 44.2% for
constipation, 24.1% for diarrhea, and 42.7% for hair loss. Detailed
numbers are reported in the Data Supplement.
Analysis per cycle showed similar results, both for agreement and
under-reporting. The estimates of under-reporting always exceeded
those calculated in the per-patient analysis. Detailed numbers are
reported in the Data Supplement.
DISCUSSION
Comparing the report of six symptomatic toxicities of anticancer
treatment by patients and physicians in a large series of patients en-
rolled onto three randomized clinical trials, we found substantial rates
of disagreement and under-reporting by physicians. The rate of
under-reporting was high for all six symptoms analyzed, even when
the analysis was limited to cases when patients had reported “very
much” toxicity in their QoL questionnaire. From this perspective,
EORTC questionnaires are appropriate instruments for this analysis,
because all the toxicity-related questions simply ask the patient for the
occurrence and severity of the symptom (ie, not higher or lower
impact of symptom on patient well being or daily activity), which
makes the patient’s answer comparable to the physician’s report.
We are aware that our analysis was not preplanned in our trials,
and the instruments used were not intended to allow a direct compar-
ison. In fact, when completing EORTC QoL questionnaires, patients
Enrolled (n = 299)
Filled in QoL questionnaire
   Any cycle (1-3)
   Cycle 1
   Cycle 2
   Cycle 3
(n = 299)
(n = 187)
(n = 178)
(n = 166)
Enrolled (n = 400)
Filled in QoL questionnaire
   Any cycle (1-3)
   Cycle 1
   Cycle 2
   Cycle 3
(n = 309)
(n = 292)
(n = 243)
(n = 172)
Filled in QoL questionnaire
   Any cycle (1-3)
   Cycle 1
   Cycle 2
   Cycle 3
(n = 1,090)
(n = 986)
(n = 840)
(n = 656)
Enrolled (n = 760)
Filled in QoL questionnaire
   Any cycle (1-3)
   Cycle 1
   Cycle 2
   Cycle 3
(n = 562)
(n = 507)
(n = 419)
(n = 318)
TORCH triallairt OCEGlairt ADLE
Cycles evaluable for comparison between patient’s and physician’s report
(n = 2,482)
Fig 1. Flow of analysis. ELDA, Elderly
Breast Cancer—Docetaxel Adjuvant; GECO,
Gemcitabine–Coxib; QoL, quality of life;
TORCH, Tarceva or Chemotherapy.
Table 1. Demographic and Clinical Characteristics of Patients Included in
Analysis (N  1,090)
Characteristic No. %
Clinical trial
ELDA 219 20.1
GECO 309 28.3
TORCH 562 51.6
Country
Italy 957 87.8
Canada 133 12.2
Sex
Male 618 56.7
Female 472 43.3
Age, years
Median 64
Range 29-81
Interquartile range 57-68
ECOG performance status
0 642 58.9
1 448 41.1
Type of disease
Early breast cancer 219 20.1
Advanced non–small-cell lung cancer 871 79.9
Treatment
Cisplatin plus gemcitabine 469 43.0
Cisplatin, gemcitabine, and rofecoxib 116 10.6
Erlotinib 286 26.2
CMF 116 10.6
Docetaxel 103 9.4
Abbreviations: CMF: cyclophosphamide, methotrexate, and fluorouracil;
ECOG, Eastern Cooperative Oncology Group; ELDA, Elderly Breast
Cancer—Docetaxel Adjuvant; GECO, Gemcitabine–Coxib; TORCH, Tarceva
or Chemotherapy.
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were explicitly asked to refer to the last week, whereas physicians were
obviously requested to report all adverse effects experienced by the
patient during the treatment cycle (lasting 4 weeks in ELDA trial and 3
weeks in GECO and TORCH trials). Many symptomatic toxicities—
typically nausea and vomiting—are usually more frequent in the first
days after treatment administration compared with the last week of
the cycle. However, the possible bias arising from this inconsis-
tency would be conservative, because the rate of symptoms re-
ported by the patients should have been even higher if they
reported on the whole duration of the treatment cycle rather than
just the previous week, potentially further increasing the rate of
physician under-reporting of toxicity.
The issue of under-reporting of toxicity in patients with cancer by
physicians has been described in several studies.2,3,15,16 Basch et al15
prospectively compared reporting of symptom occurrence and sever-
ity by patients with cancer and clinicians (physicians or nurses) in an
experimental study where clinicians were aware that their reports
would be compared with patients’ reports. The agreement was quite
low for symptoms prevalently caused by the disease and quite high,
although not complete, for potential adverse effects. In another pro-
spective blinded study, where clinicians were aware that their assess-
ments would be compared with those of patients’, agreement was
quite good for absence of toxicity but not satisfactory for grade of
adverse effects.17 Recently, significant under-reporting of symptoms
caused by androgen deprivation with or without docetaxel in patients
with prostate cancer was also reported.18 Our data suggest that report-
ing by physicians of subjective toxicity in clinical trials may be not
accurate enough. With 1,000 patients with cancer, evaluated for up
to three cycles of treatment, our analysis was conducted in a large series
of patients who were enrolled onto and prospectively observed in
clinical trials. As specified in Patients and Methods, we limited our
pooled analysis to three trials, selected because of uniform QoL instru-
ments used and timing of administration. Other randomized trials
coordinated by our clinical trials unit were not included in the analysis,
essentially because of different QoL instruments or different timing of
administration. However, our series is highly representative of the
larger cancer population, including two common types of cancer,
both elderly and younger patients, and both patients with early- and
advanced-stage disease, with only slight differences in under-
reporting by physicians in the three trials. This makes the generaliz-
ability of our findings quite high.
Several factors may explain under-reporting. First, on the physi-
cian side, there may be less attention paid to subjective toxicity, par-
ticularly for adverse effects that would not prompt treatment
modification or supportive care, for those present before treatment
initiation, and for those mild in severity. However, all six toxicities
analyzed should have been coded at least as grade 1, even if mild in
severity. Furthermore, to be conservative, we considered toxicity as
correctly reported, whatever the grade specified by the physician.
Second, at least in principle, physicians could have not reported an
adverse event because they judged it unrelated to treatment. However,
this could be true for some adverse events (like appetite loss) that are
commonly related to cancer itself (at least in patients with advanced
disease), but it is less likely for other adverse events (eg, nausea, vom-
iting, hair loss) that were probably treatment related in the majority of
cases. Third, it is possible that clinicians could be less likely to report a
toxicity that is largely expected with the drugs administered. However,
at least in principle, the opposite could also be true, and clinicians
Table 2. Per-Patient Analysis of Association Between Patient (any severity) and Physician Reporting (any grade) of Toxicity
Toxicity
No. of Evaluable
Patients
Toxicity
Reported by
Neither Patient
Nor Physician
Toxicity
Reported by
Physician but
Not Patient
Toxicity
Reported by
Patient but
Not Physician
Toxicity
Reported by
Both Patient
and Physician
Cohen’s  95% CINo. % No. % No. % No. %
Anorexia 1,090 383 35.1 28 2.6 505 46.3 174 16.0 0.15 0.12 to 0.19
Nausea 1,089 335 30.8 100 9.2 266 24.4 388 35.6 0.34 0.29 to 0.39
Vomiting 1,090 700 64.2 107 9.8 134 12.3 149 13.7 0.41 0.34 to 0.47
Constipation 1,087 501 46.1 32 2.9 384 35.3 170 15.6 0.24 0.20 to 0.29
Diarrhea 1,088 643 59.1 57 5.2 197 18.1 191 17.6 0.45 0.39 to 0.50
Hair loss 1,086 519 47.8 15 1.4 360 33.1 192 17.7 0.32 0.27 to 0.36
No. of evaluable patients may be slightly different among toxicities, because some patients did not complete all items of quality-of-life questionnaire.
74.4 
40.7
47.3
86.3
37.7
58.0
78.8
37.2
44.0
67.3
44.5
69.3
50.8
65.2
74.8
42.3
44.5
74.1
75.0
72.9
45.6
63.4
47.9
79.1
Pooled dataset
ELDA
GECO
TORCH
Anorexia
Nausea
Vomiting
Constipation
Diarrhea
Hair loss
20%0% 40% 60% 80% 100%
Fig 2. Proportion of under-reporting by physicians in whole data set and
scattered by clinical trial. Under-reporting was calculated as rate of cases where
physicians reported grade 0 toxicity in all cycles, of cases where patients
reported toxicity in  one cycle. ELDA, Elderly Breast Cancer—Docetaxel
Adjuvant; GECO, Gemcitabine–Coxib; TORCH, Tarceva or Chemotherapy.
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could be possibly more sensitive to largely expected toxicities. Looking
at the under-reporting in the two arms of the TORCH trial (Data
Supplement), the rate of under-reporting for nausea and vomiting is
higher with erlotinib than with chemotherapy (latter being expected
to produce more emesis), whereas the rate of under-reporting for
diarrhea is higher with chemotherapy than with erlotinib (which in-
cludes diarrhea among its typical adverse events). Fourth, on the
patient side, the attention paid in reporting verbally to the physician
what was reported in single items of the QoL questionnaire might be
suboptimal, with the potential assumption that the toxicity was com-
municated through the questionnaire, or because of some degree of
self censure, considering that communication with the physician also
focuses on treatment benefit, which some patients may consider more
relevant than some adverse effects. Fifth, the manner in which toxicity
is explored during verbal communication between physicians and
patients might be generic and not guided by the extensive list of
potential adverse effects included in CRFs. Sixth, there might be
under-reporting between the clinical files and the study CRF; we
cannot quantify this phenomenon, because peripheral monitoring
was not performed in these three trials.
Our analysis, based on a series of patients enrolled in 78 different
centers, documents that on average, agreement is low when we con-
sider physician report of subjective toxicities. We believe it is impor-
tant to underline that under-reporting produces underestimation of
the absolute rate of toxicity, which is highly relevant information for
patients and their physicians in clinical practice, as well as regulatory
bodies. Without an accurate estimation of the absolute rate of adverse
events, the discussion of the benefit-risk ratio of treatment can be
substantially biased, particularly for newer drugs entering standard
clinical practice, with which the treating physician might have no or
minimal previous experience.
Our findings emphasize the need for modifying the current sys-
tem of toxicity assessment in clinical trials. Specifically, a collaborative
reporting approach, where the patients directly report symptomatic
toxicity information, which is then provided to clinicians to inform
their CTCAE reporting, could improve the efficiency of reporting, and
modern technologic supports (eg, tablets) could be used to facilitate
patient reporting.1 The NCI has developed and tested an item bank
and software system aimed at directly collecting information on
symptoms and adverse events from patients with cancer participating
in clinical trials.19,20 This system is called the patient-reported out-
comes version of the CTCAE (PRO-CTCAE). Considering the
substantial risk of under-reporting when the description of symptom-
atic toxicity is based only on physicians’ reports, we agree that the
PRO-CTCAE system could represent a valid instrument to improve
adverse event reporting data quality and comprehensiveness, promote
communication between patients and clinicians, and improve clinical
decision making.20,21 Research is currently ongoing on the implemen-
tation of this tool in cancer clinical trials.
In conclusion, our analysis shows that even when prospectively
collected within randomized controlled trials, subjective toxicities as-
sociated with anticancer treatments are at high risk of under-reporting
by physicians. Our findings strongly support the incorporation of
patient-reported information into toxicity reports in clinical trials.
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GLOSSARY TERMS
health-related quality of life (HRQoL): a broad multi-
dimensional concept that usually includes self-reported measures
of physical and mental health.
patient-reported outcomes: questionnaires used in a clinical
setting to systemically collect information directly from the patient.
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